Publication | Open Access

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

UrologyOncologyGenitourinary CancerAbiraterone AcetateCancer ManagementClinical TrialsPharmacotherapyProstatic DiseaseMedicine